Furmonertinib in First-line Treatment of Patients With CNS Metastatic EGFR Mutation Positive NSCLC

  • End date
    Mar 31, 2025
  • participants needed
  • sponsor
    Hunan Province Tumor Hospital
Updated on 2 June 2022
lung carcinoma


EGFR mutation positive advanced NSCLC patients with CNS metastases have poor prognosis, second-line furmonertinib dose at 160mg level in EGRF T790M mutation positive CNS metastatic NSCLC have provided relevant benefit with a high CNS PFS and CNS ORR. Whether CNS metastatic EGFR mutation positive NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported. This study aims to investigate the efficacy and safety of furmonertinib 160mg per day in CNS metastatic EGFR mutant patients under first-line treatment of advanced NSCLC setting.


This is a single arm, multicenter study which will recruit about 40 patients in China.

The study is designed to evaluate the efficacy and safety of furmonertinib in the first-line treatment of patients with EGFR mutations in advanced NSCLC with CNS metastases.

Furmonertinib is a third generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets multiple Epidermal Growth Factor Receptor (EGFR) mutations. It will be administered orally at a dose of 160 mg per time, Q.D.

Condition Non-Small Cell Lung Cancer
Treatment Furmonertinib
Clinical Study IdentifierNCT05379803
SponsorHunan Province Tumor Hospital
Last Modified on2 June 2022


Yes No Not Sure

Inclusion Criteria

Provide informed consent prior to any study specific procedures
at least 18 years of age
ECOG PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks, life expectancy ≥12 weeks
Histologically or cytologically confirmed metastatic Non-Small Cell Lung Cancer (NSCLC)
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together
Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC)
According to RECIST 1.1, patients must have at least one central nervous system (CNS) metastatic tumor lesion at baseline that meets the following requirements: accurately and repeatably measurable at baseline, have no radiotherapy or biopsy
For premenopausal women with childbearing potential, a pregnancy test must be performed within 14 days before the first dose, and the pregnancy test (blood or urine test) must be negative; female subjects must not be lactating
Willing to use contraception
Voluntary and agree to follow the study treatment protocol as well as follow-up plan, and can accept the oral medicine treatment

Exclusion Criteria

small cell lung carcinoma
History of hypersensitivity to active or inactive excipients of investigational product (IP) or drugs with a similar chemical structure or class to investigational product (IP)
Confirmed EGFR 20 exon insertion mutations at any time after the initial diagnosis
Patient who receive prior treatment including any of the following
Any Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)
The patients who have received intrapleural perfusion therapy can only be enrolled 28 days or more after the pleural effusion is stable
Major surgery within 4 weeks of the first dose of investigational product (IP)
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP
CYP3A4 strong inhibitor or strong inducer is used within 7 days prior to the first dose, or need to receive these drugs during the study period
Traditional Chinese medicine and traditional Chinese medicine preparations with anti-tumor as indications and with adjuvant treatment of tumor is used within 7 days prior to the first dose, or need to receive these drugs during the study period
Patients who are receiving drugs known to prolong QTc interval or may cause torsade de pointe and need to continue to receive these drugs during the study period
The time from the treatment with any other investigational product or its analogue to the first dose does not exceed 5 half-lives of the drug or 14 days, whichever is longer
Prior treatment with any systemic anti-cancer therapy for advanced Non-Small Cell Lung Cancer (NSCLC) including chemotherapy, biologic therapy, target therapy, immunotherapy, or any investigational drug, except neoadjuvant or adjuvant therapy before 6 months prior to the first dose IP
At the beginning of study treatment, any unresolved toxic reaction to prior treatment is present, which exceeds Grade 1 in accordance with Common Terminology Criteria for Adverse Events (CTCAE) (except for alopecia), and exceeds Grade 2 for prior platinum treatment-related neuropathy
Spinal cord compression; symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids
Diagnosed other malignant tumors or had a history of other malignant tumors in last 5 years, except for skin basal cell carcinoma, cervical carcinoma in situ and breast ductal carcinoma in situ which have been effectively controlled
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of IP
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, and active infection, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial
Past medical history of Interstitial Lung Disease (ILD), drug-induced Interstitial Lung Disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active Interstitial Lung Disease
Any evidence of corneal injury
Inadequate bone marrow reserve or organ function
QT prolongation or any clinically important abnormalities in rhythm and heart function
Patients who may have poor compliance with the research procedures and requirements, etc., as judged by investigators
Pregnancy or lactation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note